Penumbra, Inc.
NYSE•PEN
CEO: Mr. Adam Elsesser J.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2015-09-18
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
連絡先情報
時価総額
$13.26B
PER (TTM)
74.5
32.6
配当利回り
--
52週高値
$362.41
52週安値
$221.26
52週レンジ
順位28Top 16.1%
5.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$385.39M+0.00%
直近4四半期の推移
EPS
$1.21+0.00%
直近4四半期の推移
フリーCF
$68.05M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth 17.5% Total revenue reached $1.404 B USD in 2025, marking a 17.5% increase from the prior year's $1.195 B USD.
Profitability Surge Net income dramatically improved to $177.7 M USD in 2025, compared to only $14.0 M USD reported in 2024.
Margin Expansion Gross margin increased 3.9 percentage points to 67.1% in 2025, benefiting from favorable product mix and productivity.
Acquisition Agreement Signed Entered Merger Agreement in January 2026 to be acquired by Boston Scientific for approximately $14.5 B enterprise value.
リスク要因
Merger Completion Uncertainty Closing the Boston Scientific Merger is subject to stockholder and regulatory approvals; failure could cause stock price decline.
Product Obsolescence Risk Success depends on anticipating technology advancements; delays in new product launches may impede market entry and sales generation.
Reimbursement Availability Risk Commercial success relies on adequate third-party reimbursement levels, which are subject to change and increasing cost containment pressures.
High Inventory Working Capital Maintaining high inventory levels, especially consignment coils, consumes significant working capital and risks obsolescence write-downs.
見通し
Focus on Customer Penetration Future growth requires penetrating current customer base and expanding user base among specialist physicians in target end markets.
International Growth Investment Intent to grow internationally requires substantial spending to expand direct sales capabilities in new and existing geographic areas.
Continued R&D Investment Plan to continue substantial investments in developing innovative, proprietary products to maintain competitive advantage and efficacy.
Merger Expected Closing The acquisition by Boston Scientific is expected to close by the end of 2026, contingent upon customary closing conditions being met.
同業比較
売上高 (TTM)
$45.43B
$13.64B
$13.18B
粗利益率 (最新四半期)
92.4%
72.0%
68.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| PEN | $13.26B | 74.5 | 13.4% | 12.0% |
| ALGN | $12.64B | 30.8 | 10.4% | 1.8% |
| ELAN | $12.52B | -53.9 | -3.5% | 30.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
5.9%
安定成長
4四半期純利益CAGR
6.5%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月21日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし